Bioventix Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Peter Harrison
Chief executive officer
UK£387.8k
Total compensation
CEO salary percentage | 59.3% |
CEO tenure | no data |
CEO ownership | 5.7% |
Management average tenure | no data |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Estimating The Fair Value Of Bioventix PLC (LON:BVXP)
Jun 19Bioventix's (LON:BVXP) Dividend Will Be £0.68
Mar 29We Think Shareholders May Consider Being More Generous With Bioventix PLC's (LON:BVXP) CEO Compensation Package
Dec 01Bioventix (LON:BVXP) Is Increasing Its Dividend To £0.62
Mar 30Bioventix (LON:BVXP) Is Increasing Its Dividend To UK£0.52
Mar 31Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?
Mar 29Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?
Mar 14What Does Bioventix's (LON:BVXP) CEO Pay Reveal?
Feb 27Shareholders of Bioventix (LON:BVXP) Must Be Delighted With Their 364% Total Return
Jan 31Is Bioventix PLC (LON:BVXP) Popular Amongst Insiders?
Jan 18Is Bioventix PLC's (LON:BVXP) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 06Here's How We Evaluate Bioventix PLC's (LON:BVXP) Dividend
Dec 23Does Bioventix's (LON:BVXP) CEO Salary Compare Well With Industry Peers?
Nov 28CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | UK£388k | UK£230k | UK£8m |
Mar 31 2024 | n/a | n/a | UK£8m |
Dec 31 2023 | n/a | n/a | UK£9m |
Sep 30 2023 | n/a | n/a | UK£9m |
Jun 30 2023 | UK£282k | UK£196k | UK£8m |
Mar 31 2023 | n/a | n/a | UK£8m |
Dec 31 2022 | n/a | n/a | UK£8m |
Sep 30 2022 | n/a | n/a | UK£8m |
Jun 30 2022 | UK£250k | UK£184k | UK£8m |
Mar 31 2022 | n/a | n/a | UK£7m |
Dec 31 2021 | n/a | n/a | UK£7m |
Sep 30 2021 | n/a | n/a | UK£7m |
Jun 30 2021 | UK£304k | UK£178k | UK£7m |
Mar 31 2021 | n/a | n/a | UK£7m |
Dec 31 2020 | n/a | n/a | UK£7m |
Sep 30 2020 | n/a | n/a | UK£7m |
Jun 30 2020 | UK£285k | UK£187k | UK£7m |
Mar 31 2020 | n/a | n/a | UK£7m |
Dec 31 2019 | n/a | n/a | UK£7m |
Sep 30 2019 | n/a | n/a | UK£6m |
Jun 30 2019 | UK£322k | UK£175k | UK£6m |
Mar 31 2019 | n/a | n/a | UK£6m |
Dec 31 2018 | n/a | n/a | UK£6m |
Sep 30 2018 | n/a | n/a | UK£6m |
Jun 30 2018 | UK£358k | UK£165k | UK£6m |
Compensation vs Market: Peter's total compensation ($USD492.22K) is below average for companies of similar size in the UK market ($USD730.71K).
Compensation vs Earnings: Peter's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Peter Harrison (66 yo)
no data
Tenure
UK£387,779
Compensation
Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | no data | UK£387.78k | 5.69% £ 9.8m | |
CFO & Director | 4.4yrs | UK£97.33k | 0.021% £ 36.7k | |
Independent Non-Executive Chairman | 20.1yrs | UK£43.55k | 0.30% £ 511.5k | |
Independent Non-Executive Director | 1.6yrs | UK£30.00k | no data |
4.4yrs
Average Tenure
65yo
Average Age
Experienced Board: BVXP's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 16:52 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioventix PLC is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Buxton | Cavendish |
null null | Cavendish |
Adam McCarter | Cavendish |